Neurotherapeutics Ltd
Neurotherapeutics Solutions Ltd is a medical device company targeting neurological disorders with an initial focus on products to empower individuals with Tourette Syndrome to control their condition without surgical or pharmaceutical interventions.

hand in hand with you on life’s journey
Faculty of Medicine / Faculty of Science
Profile
The company’s approach is based on the therapeutic use of peripheral somatosensory stimulation to adjust brain rhythms using safe non invasive devices.
News and press releases
Researchers develop new platform that could replace the use of animals in research
- 3rd August 2023 11:20 am·
Spin-out company launched to deliver gene therapy during bone repair surgery
- 13th June 2023 11:48 am·
Lewis Capaldi visits the Neupulse office to try out our wearable wrist device
- 30th January 2023 3:04 pm·
Neupulse raises £918k in a second round of funding
- 20th January 2023 1:05 pm·
Alevin wins Best Biotech Startup Company award at the prestigious OBN Awards 2022
- 19th November 2022 2:34 pm·
SurePulse and partners land £1.4m Innovate UK award
- 2nd November 2022 1:37 pm·
PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test
- 27th October 2022 11:40 am·
Nottingham trio share award for brain imaging innovation
- 27th October 2022 11:28 am·
Face and voice recognition technology set to transform diagnosis of perinatal depression
- 20th October 2022 4:01 pm·
BlueSkeye AI wins ‘One to Watch’ Award at Medilink Business Awards 2022
- 2nd February 2022 12:22 pm·
Data privacy startup ID Ward raises €1.1 million to launch its decentralised advertising technology
- 2nd February 2022 11:53 am·
NuVision Biotherapies announces the appointment of its new Chief Executive Officer and Chief Operating Officer
- 13th January 2022 11:43 am·
Since the research was published last year we have seen a huge amount of interest in our results from people with Tourette Syndrome across the world, who are often desperate to find a way to control their tics, which is why we are delighted to be taking the research to the next stage via the formation of the spin-out and the clinical trial.

Prof Stephen Jackson, Faculty of Science